Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
Pfizer Inc is developing tremelimumab, a fully human monoclonal IgG2 antibody against cytotoxic T-lymphocyte-associated antigen, for the potential intravenous treatment of cancer. Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer.
Tarhini
Ahmad A
AA
University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA. tarhiniaa@upmc.edu
Kirkwood
John M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology*; D000943:Antigens, Differentiation / Q000276:immunology*; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D007074:Immunoglobulin G; C520704:tremelimumab